Smith & Nephew rating upgraded to “buy” — 5 things to know

Smith & Nephew was upgraded to a “buy” rating by equities research analysts at Goldman Sachs, according to a Dakota Financial News report.

Advertisement

Here are five things to know about the company’s stock:

 

•    Goldman Sachs upgraded Smith & Nephew from a “neutral” rating.
•    Smith & Nephew has a one-year low of $28.87 and a one-year high of $40.38.
•    The stock’s 50-day moving average is $35 and its 200-day moving average is $34.
•    The company has a market cap of $15.32 billion.
•    Currently, the stock has an average rating of “hold” and an average price target of $63.30.

More articles on devices:
10 things to know about the PRP market through 2020
Zimmer CEO sells stock in $150k transaction — 5 key notes
John Dahldorf becomes new Benvenue Medical CFO — 5 key notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • Since March 25, there have been two key developments in lawsuits involving spine medtech companies. 1. The U.S. Court of…

  • The highest-paid CFOs at spine and orthopedic medtech companies saw total compensation reaching in the mid-single digits and beyond. Here…

Advertisement

Comments are closed.